The point of care infectious disease testing market size has grown rapidly in recent years. It will grow from $4.78 billion in 2025 to $5.44 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to rising incidence of infectious diseases, increased demand for rapid diagnostics, expansion of decentralized healthcare delivery, availability of lateral flow testing technologies, growing use of rapid screening in hospitals.
The point of care infectious disease testing market size is expected to see rapid growth in the next few years. It will grow to $9.02 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing adoption of self-testing solutions, expansion of molecular poc diagnostics, rising investments in digital health integration, increasing focus on outbreak preparedness, growing demand for low-cost rapid tests. Major trends in the forecast period include increasing adoption of rapid molecular poc tests, rising demand for home-based infectious disease testing, growing use of multiplex diagnostic kits, expansion of portable diagnostic instruments, enhanced focus on early disease detection.
The rising incidence of contagious diseases is expected to drive the growth of the point of care infectious disease testing market going forward. A contagious disease is an illness that can spread from one individual to another through direct contact, airborne droplets, or other transmission pathways. The increasing occurrence of contagious diseases is largely attributed to higher levels of human mobility, as greater movement across regions and countries enables faster and broader spread of infectious agents. Point of care infectious disease testing supports rapid detection and diagnosis, allowing timely treatment and helping to limit transmission within communities. For instance, in June 2024, according to the UK Health Security Agency, a UK-based government body, between week 40 of 2022 and week 15 of 2023, 108 NHS trusts in England reported 1,681 critical care admissions due to confirmed influenza. By comparison, the previous flu season recorded only 182 admissions across 114 trusts, which later increased to 316 by week 39 of 2022. Therefore, the rising incidence of contagious diseases is driving the growth of the point of care infectious disease testing market.
Major companies operating in the point of care infectious disease testing market are focusing on the integration of advanced technologies, such as proprietary microfluidic technology, to improve test accuracy, shorten time to results, and enhance patient outcomes. Proprietary microfluidic technology involves specialized systems that control and analyze very small fluid volumes at the microscale, enabling rapid, precise, and cost effective diagnostics. This technology supports point of care infectious disease testing by enabling fast, on site pathogen detection with integrated sample processing and result generation, reducing reliance on centralized laboratory facilities. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, introducing the world’s first point of care testing solution for direct antimicrobial susceptibility detection. Using advanced microfluidic technology, the system allows rapid identification of bacterial infections and assessment of antimicrobial effectiveness, significantly reducing processing time compared with conventional methods. The system consists of a compact desktop analyzer and single use sample cartridges, making it suitable for near patient settings such as primary care clinics. It is designed to support faster and more accurate antimicrobial therapy decisions and contributes to efforts to address antimicrobial resistance through improved diagnostic efficiency.
In July 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, acquired LumiraDx’s point of care technology for $295 million. Through this acquisition, Roche aims to expand global access to decentralized diagnostic testing by incorporating LumiraDx’s flexible point of care platform into its diagnostics portfolio, enabling timely and actionable results across primary care and underserved healthcare environments. LumiraDx is a US-based medical equipment manufacturer specializing in point of care infectious disease testing solutions.
Major companies operating in the point of care infectious disease testing market are Cardinal Health, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc., Cepheid Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., GenBody Inc.
North America was the largest region in the point of care infectious disease testing market in 2025. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care infectious disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point of care infectious disease testing market by increasing costs of imported reagents, diagnostic consumables, microfluidic components, and electronic modules used in portable instruments and test kits. Healthcare providers in North America and Europe are most affected due to reliance on globally sourced reagents and analyzers, while Asia-Pacific faces pricing pressure on export-oriented diagnostic manufacturing. These tariffs are increasing test kit prices and affecting procurement budgets for hospitals and diagnostic centers. However, they are also encouraging local reagent production, regional manufacturing of diagnostic devices, and supply chain diversification to improve long-term testing availability.
The point of care infectious disease testing market research report is one of a series of new reports that provides point of care infectious disease testing market statistics, including point of care infectious disease testing industry global market size, regional shares, competitors with a point of care infectious disease testing market share, detailed point of care infectious disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the point of care infectious disease testing industry. This point of care infectious disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point of care infectious disease testing involves diagnostic tests conducted at or close to the location of patient care, such as hospitals, clinics, physician offices, or home settings. These tests are designed to rapidly and accurately identify infectious diseases, delivering immediate results that support timely treatment decisions. Point of care tests are generally easy to use, require minimal equipment, and provide results within minutes to hours, making them suitable for situations where prompt diagnosis is essential.
The primary product types in point of care infectious disease testing include kits and reagents, and instruments. Kits and reagents consist of pre prepared components used in point of care diagnostics to quickly identify infectious agents through reactions with patient samples. The technologies employed include lateral flow immunoassay, agglutination tests, flow through tests or immunoconcentration assays, molecular diagnostics, and others. The diseases tested include human immunodeficiency virus, clostridium difficile, hepatitis B virus, pneumonia or streptococcus associated infections, respiratory syncytial virus, human papillomavirus, influenza, and others. These point of care tests are used by a range of end users, including hospitals, diagnostic centers, research and academic institutions, home care environments, and others.
The point-of-care infectious disease testing market consists of revenues earned by entities by providing services such as rapid diagnostic testing, disease screening, and onsite sample analysis for infectious conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care infectious disease testing market also includes sales of handheld analyzers, lateral flow assays, molecular testing devices, and related consumables used for the immediate detection of infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point of care infectious disease testing market size is expected to see rapid growth in the next few years. It will grow to $9.02 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing adoption of self-testing solutions, expansion of molecular poc diagnostics, rising investments in digital health integration, increasing focus on outbreak preparedness, growing demand for low-cost rapid tests. Major trends in the forecast period include increasing adoption of rapid molecular poc tests, rising demand for home-based infectious disease testing, growing use of multiplex diagnostic kits, expansion of portable diagnostic instruments, enhanced focus on early disease detection.
The rising incidence of contagious diseases is expected to drive the growth of the point of care infectious disease testing market going forward. A contagious disease is an illness that can spread from one individual to another through direct contact, airborne droplets, or other transmission pathways. The increasing occurrence of contagious diseases is largely attributed to higher levels of human mobility, as greater movement across regions and countries enables faster and broader spread of infectious agents. Point of care infectious disease testing supports rapid detection and diagnosis, allowing timely treatment and helping to limit transmission within communities. For instance, in June 2024, according to the UK Health Security Agency, a UK-based government body, between week 40 of 2022 and week 15 of 2023, 108 NHS trusts in England reported 1,681 critical care admissions due to confirmed influenza. By comparison, the previous flu season recorded only 182 admissions across 114 trusts, which later increased to 316 by week 39 of 2022. Therefore, the rising incidence of contagious diseases is driving the growth of the point of care infectious disease testing market.
Major companies operating in the point of care infectious disease testing market are focusing on the integration of advanced technologies, such as proprietary microfluidic technology, to improve test accuracy, shorten time to results, and enhance patient outcomes. Proprietary microfluidic technology involves specialized systems that control and analyze very small fluid volumes at the microscale, enabling rapid, precise, and cost effective diagnostics. This technology supports point of care infectious disease testing by enabling fast, on site pathogen detection with integrated sample processing and result generation, reducing reliance on centralized laboratory facilities. For instance, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the PA-100 AST System in Europe, introducing the world’s first point of care testing solution for direct antimicrobial susceptibility detection. Using advanced microfluidic technology, the system allows rapid identification of bacterial infections and assessment of antimicrobial effectiveness, significantly reducing processing time compared with conventional methods. The system consists of a compact desktop analyzer and single use sample cartridges, making it suitable for near patient settings such as primary care clinics. It is designed to support faster and more accurate antimicrobial therapy decisions and contributes to efforts to address antimicrobial resistance through improved diagnostic efficiency.
In July 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, acquired LumiraDx’s point of care technology for $295 million. Through this acquisition, Roche aims to expand global access to decentralized diagnostic testing by incorporating LumiraDx’s flexible point of care platform into its diagnostics portfolio, enabling timely and actionable results across primary care and underserved healthcare environments. LumiraDx is a US-based medical equipment manufacturer specializing in point of care infectious disease testing solutions.
Major companies operating in the point of care infectious disease testing market are Cardinal Health, F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, bioMérieux Société Anonyme, QuidelOrtho Corporation, Bio Rad Laboratories Inc., DiaSorin Società per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Société Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, bioLytical Laboratories Inc., Cepheid Inc., LumiraDx UK Ltd., Meridian Bioscience Inc., GenBody Inc.
North America was the largest region in the point of care infectious disease testing market in 2025. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in the point of care infectious disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care infectious disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point of care infectious disease testing market by increasing costs of imported reagents, diagnostic consumables, microfluidic components, and electronic modules used in portable instruments and test kits. Healthcare providers in North America and Europe are most affected due to reliance on globally sourced reagents and analyzers, while Asia-Pacific faces pricing pressure on export-oriented diagnostic manufacturing. These tariffs are increasing test kit prices and affecting procurement budgets for hospitals and diagnostic centers. However, they are also encouraging local reagent production, regional manufacturing of diagnostic devices, and supply chain diversification to improve long-term testing availability.
The point of care infectious disease testing market research report is one of a series of new reports that provides point of care infectious disease testing market statistics, including point of care infectious disease testing industry global market size, regional shares, competitors with a point of care infectious disease testing market share, detailed point of care infectious disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the point of care infectious disease testing industry. This point of care infectious disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point of care infectious disease testing involves diagnostic tests conducted at or close to the location of patient care, such as hospitals, clinics, physician offices, or home settings. These tests are designed to rapidly and accurately identify infectious diseases, delivering immediate results that support timely treatment decisions. Point of care tests are generally easy to use, require minimal equipment, and provide results within minutes to hours, making them suitable for situations where prompt diagnosis is essential.
The primary product types in point of care infectious disease testing include kits and reagents, and instruments. Kits and reagents consist of pre prepared components used in point of care diagnostics to quickly identify infectious agents through reactions with patient samples. The technologies employed include lateral flow immunoassay, agglutination tests, flow through tests or immunoconcentration assays, molecular diagnostics, and others. The diseases tested include human immunodeficiency virus, clostridium difficile, hepatitis B virus, pneumonia or streptococcus associated infections, respiratory syncytial virus, human papillomavirus, influenza, and others. These point of care tests are used by a range of end users, including hospitals, diagnostic centers, research and academic institutions, home care environments, and others.
The point-of-care infectious disease testing market consists of revenues earned by entities by providing services such as rapid diagnostic testing, disease screening, and onsite sample analysis for infectious conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care infectious disease testing market also includes sales of handheld analyzers, lateral flow assays, molecular testing devices, and related consumables used for the immediate detection of infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point of Care Infectious Disease Testing Market Characteristics
3. Point of Care Infectious Disease Testing Market Supply Chain Analysis
4. Global Point of Care Infectious Disease Testing Market Trends and Strategies
5. Point of Care Infectious Disease Testing Market Analysis of End Use Industries
7. Global Point of Care Infectious Disease Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point of Care Infectious Disease Testing Total Addressable Market (TAM) Analysis for the Market
9. Point of Care Infectious Disease Testing Market Segmentation
10. Point of Care Infectious Disease Testing Market Regional and Country Analysis
11. Asia-Pacific Point of Care Infectious Disease Testing Market
12. China Point of Care Infectious Disease Testing Market
13. India Point of Care Infectious Disease Testing Market
14. Japan Point of Care Infectious Disease Testing Market
15. Australia Point of Care Infectious Disease Testing Market
16. Indonesia Point of Care Infectious Disease Testing Market
17. South Korea Point of Care Infectious Disease Testing Market
18. Taiwan Point of Care Infectious Disease Testing Market
19. South East Asia Point of Care Infectious Disease Testing Market
20. Western Europe Point of Care Infectious Disease Testing Market
21. UK Point of Care Infectious Disease Testing Market
22. Germany Point of Care Infectious Disease Testing Market
23. France Point of Care Infectious Disease Testing Market
24. Italy Point of Care Infectious Disease Testing Market
25. Spain Point of Care Infectious Disease Testing Market
26. Eastern Europe Point of Care Infectious Disease Testing Market
27. Russia Point of Care Infectious Disease Testing Market
28. North America Point of Care Infectious Disease Testing Market
29. USA Point of Care Infectious Disease Testing Market
30. Canada Point of Care Infectious Disease Testing Market
31. South America Point of Care Infectious Disease Testing Market
32. Brazil Point of Care Infectious Disease Testing Market
33. Middle East Point of Care Infectious Disease Testing Market
34. Africa Point of Care Infectious Disease Testing Market
36. Point of Care Infectious Disease Testing Market Competitive Landscape and Company Profiles
37. Point of Care Infectious Disease Testing Market Other Major and Innovative Companies
40. Point of Care Infectious Disease Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Point Of Care Infectious Disease Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point of care infectious disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point of care infectious disease testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point of care infectious disease testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Kits And Reagents; Instruments2) By Technology: Lateral Flow Immunoassay; Agglutination Test; Flow-through Test Or Immunoconcentration Assay; Molecular Diagnostics; Other Technologies
3) By Disease: Human Immunodeficiency Virus Point-of-Care Testing; Clostridium Difficile Point-of-Care Testing; Hepatitis B Virus Point-of-Care Testing; Pneumonia or Streptococcus Associated Infections; Respiratory Syncytial Virus Point-of-Care Testing; Human Papillomavirus Point-of-Care Testing; Influenza Or Flu Point-of-Care Testing; Other Diseases
4) By End Use: Hospitals; Diagnostic Centers; Research and Academic Institutes; Homecare Settings; Other End Users
Subsegments:
1) By Kits And Reagents: Test Kits; Reagents2) By Instruments: Portable Devices; Automated Analyzers
Companies Mentioned: Cardinal Health; F Hoffmann La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Becton Dickinson and Company; bioMérieux Société Anonyme; QuidelOrtho Corporation; Bio Rad Laboratories Inc.; DiaSorin Società per Azioni; Danaher Corporation; Cue Health Inc.; Nova Biomedical Corporation; Seegene Incorporated; Biosynex Société Anonyme; Trivitron Healthcare Private Limited; EKF Diagnostics Holdings plc; Trinity Biotech Public Limited Company; bioLytical Laboratories Inc.; Cepheid Inc.; LumiraDx UK Ltd.; Meridian Bioscience Inc.; GenBody Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point of Care Infectious Disease Testing market report include:- Cardinal Health
- F Hoffmann La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Siemens Healthineers AG
- Becton Dickinson and Company
- bioMérieux Société Anonyme
- QuidelOrtho Corporation
- Bio Rad Laboratories Inc.
- DiaSorin Società per Azioni
- Danaher Corporation
- Cue Health Inc.
- Nova Biomedical Corporation
- Seegene Incorporated
- Biosynex Société Anonyme
- Trivitron Healthcare Private Limited
- EKF Diagnostics Holdings plc
- Trinity Biotech Public Limited Company
- bioLytical Laboratories Inc.
- Cepheid Inc.
- LumiraDx UK Ltd.
- Meridian Bioscience Inc.
- GenBody Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.44 Billion |
| Forecasted Market Value ( USD | $ 9.02 Billion |
| Compound Annual Growth Rate | 13.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
